Alnylam Pharmaceuticals, Inc. (FRA:DUL)

Market Cap	51.66B
Revenue (ttm)	2.74B
Net Income (ttm)	37.13M
Shares Out	n/a
EPS (ttm)	0.28
PE Ratio	1,391.26
Forward PE	42.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	12
Open	384.50
Previous Close	386.20
Day's Range	384.50 - 395.90
52-Week Range	198.70 - 423.00
Beta	n/a
RSI	49.83
Earnings Date	Feb 20, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DUL

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD